Biophan forms scientific advisory board for Myotech

By E. Janene Geiss

Philadelphia, July 25 - Biophan Technologies, Inc. announced Tuesday the formation of a scientific advisory board for Myotech LLC to oversee the development, clinical evaluation and commercialization of Myo-Vad, a novel cardiac assist device designed to treat many types of heart failure.

Biophan holds a 42% interest in Myotech with rights to acquire a majority position and is leading Myotech's business development activities, according to a company news release.

The scientific advisory board comprises Mark P. Anstadt, the co-inventor of the Myo-Vad device; James Lowe, who pioneered early application of the Myo-Vad technology; Douglas A. Mann, who is involved in many aspects of addressing heart failure; Carmelo Milano, whose research and clinical interests include gene therapy approaches to cardiovascular diseases; and Benjamin Sun, whose research interests include development of chronic heart failure models supported by mechanical support.

Myotech is a privately held medical technology development company.

Biophan, based in Rochester, N.Y., develops technologies for the medical device industry.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.